Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Phase 2 Unknown 50 enrolled National Hospital Organization Nagoya Medical Center Central Japan Lung Study Group · collab Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion score (TPS) of less than 50%.

Timeline

Start: 2020-05-25
Primary completion: 2023-05
Completion: 2024-11

Publications

Kogure Y, Hashimoto H, Daga H, Fukuda Y, Bessho A, Yamada T, Toi Y, Kimura T, Yoshioka H, Azuma K, Furuya N, Fukui Y, Saito AM, Yamamoto N, Saka H, Kondo M. Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50. JTO Clin Res Rep. 2024 Dec 24;6(3):100784. doi: 10.1016/j.jtocrr.2024.100784. eCollection 2025 Mar.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Summary

Timeline

Publications

Drugs

Indications